Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

Phase 1 Completed 15 enrolled Trio Medicines Ltd. Ferring Pharmaceuticals · collab

RandomizedCrossoverDouble-blindBasic science

Summary

The objectives of the study were: * To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. * To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.

Timeline

Start: 1996-05
Primary completion: 1996-06
Completion: 1996-06

Publications

Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther. 2012 Jul;36(2):181-9. doi: 10.1111/j.1365-2036.2012.05143.x. Epub 2012 May 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	netazepide	Protein / enzyme biologic	0.5 mg	Oral
Subject	netazepide	Protein / enzyme biologic	5 mg	Oral
Subject	netazepide	Protein / enzyme biologic	25 mg	Oral
Subject	netazepide	Protein / enzyme biologic	50 mg	Oral
Subject	netazepide	Protein / enzyme biologic	100 mg	Oral

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

Summary

Timeline

Publications

Drugs

Indications